Division of Pharmacy and Optometry, School of Health Science, University of Manchester, Oxford Road, Manchester, M13 9PT, UK.
Department of Pharmaceutical Science, Faculty of Pharmacy, Umm Al-Qura University, Makkah, 21955, Saudi Arabia.
Macromol Biosci. 2020 Jan;20(1):e1900283. doi: 10.1002/mabi.201900283. Epub 2019 Nov 18.
This review focuses on fibrin, starting from biological mechanisms (its production from fibrinogen and its enzymatic degradation), through its use as a medical device and as a biomaterial, and finally discussing the techniques used to add biological functions and/or improve its mechanical performance through its molecular engineering. Fibrin is a material of biological (human, and even patient's own) origin, injectable, adhesive, and remodellable by cells; further, it is nature's most common choice for an in situ forming, provisional matrix. Its widespread use in the clinic and in research is therefore completely unsurprising. There are, however, areas where its biomedical performance can be improved, namely achieving a better control over mechanical properties (and possibly higher modulus), slowing down degradation or incorporating cell-instructive functions (e.g., controlled delivery of growth factors). The authors here specifically review the efforts made in the last 20 years to achieve these aims via biomimetic reactions or self-assembly, as much via formation of hybrid materials.
这篇综述主要关注纤维蛋白,首先从生物学机制(纤维蛋白原的产生及其酶解)开始,然后介绍其作为医疗器械和生物材料的应用,最后讨论了通过分子工程添加生物功能和/或改善其机械性能的相关技术。纤维蛋白是一种具有生物(人类,甚至是患者自身)来源的材料,可注射、具有黏附性,并且可以被细胞重塑;此外,它还是自然界中最常见的用于原位形成、临时基质的选择。因此,它在临床和研究中的广泛应用是完全不足为奇的。然而,仍有一些领域可以改进其生物医学性能,例如更好地控制机械性能(可能提高模量)、减缓降解或加入具有细胞导向功能的物质(例如,生长因子的控制释放)。本文作者特别综述了过去 20 年来通过仿生反应或自组装来实现这些目标的努力,包括形成杂化材料。